Nasdaq:US$13.13 (-0.20) | HKEX:HK$20.30 (-0.52) | AIM:£1.97 (-0.05)
News & Presentations
Previous Article   |   Next Article
Presentations | 22 Jan 2022

ASCO GI 2022 | Phase 1/1b trial of fruquintinib in patients with advanced solid tumors: preliminary results of the dose expansion cohorts in refractory metastatic colorectal cancer